GoldenGolden
Advanced Search
Bristol-Myers Squibb

Bristol-Myers Squibb

Bristol-Myers Squibb is a New York City-based company founded in 1989.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

May 19, 2021
Bristol Myers Squibb announces a collaboration agreement with Exscientia, an Artificial Intelligence (AI)-focused biopharma company, that could hit $1,200,000,000.
August 7, 2007
Bristol-Myers Squibb raises a $15,500,000 series C round from Atlas Venture, HBM BioVentures, Polaris Partners and Venrock.
June 26, 2006
Bristol-Myers Squibb raises a $27,000,000 series B round from Atlas Venture, Polaris Partners and Venrock.

Funding rounds

People

Name
Role
LinkedIn

Andrew Boutcher

Investor

Marine Rubat du Mérac

Attorney

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
May 21, 2021
BioSpace
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient - read this article along with other careers information, tips and advice on BioSpace
May 20, 2021
BioSpace
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy - read this article along with other careers information, tips and advice on BioSpace
BioSpace
May 20, 2021
BioSpace
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Manuel Hidalgo Medina, M.D., Ph.D., to the Board, effective June 1, 2021.
May 19, 2021
BioSpace
Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination - read this article along with other careers information, tips and advice on BioSpace
DarwinHealth
May 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- DarwinHealth, una empresa de biotecnología con sede en la ciudad de Nueva York, anunció hoy una colaboración en investigación científica con la...
DarwinHealth
May 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- DarwinHealth, ein Biotechnologieunternehmen mit Sitz in New York City, gab heute eine wissenschaftliche Forschungszusammenarbeit mit...
DarwinHealth
May 6, 2021
www.prnewswire.com:443
/PRNewswire/ -- A DarwinHealth, uma empresa de biotecnologia com sede em Nova York, anunciou hoje uma colaboração de pesquisa científica com a Bristol-Myers...
DarwinHealth
May 6, 2021
www.prnewswire.com:443
/PRNewswire/ -- DarwinHealth, una empresa de biotecnología con sede en Nueva York, anunció hoy una colaboración de investigación científica con Bristol-Myers...
April 30, 2021
BioSpace
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma - read this article along with other careers information, tips and advice on BioSpace
April 23, 2021
BioSpace
Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission - read this article along with other careers information, tips and advice on BioSpace
April 16, 2021
BioSpace
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma.... - read this article along with other careers information, tips and advice on BioSpace
April 14, 2021
BioSpace
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma - read this article along with other careers information, tips and advice on BioSpace
BioSpace
April 10, 2021
BioSpace
Nearly a quarter of patients who received Opdivo plus chemotherapy showed no evidence of cancer cells in tissue removed during surgery vs. 2.2% of patients who received chemotherapy alone
April 8, 2021
BioSpace
Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit - read this article along with other careers information, tips and advice on BioSpace
November 24, 2020
BioSpace
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma - read this article along with other careers information, tips and advice on BioSpace
November 17, 2020
BioSpace
Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company's Leading Cardiovascular Franchise - read this article along with other careers information, tips and advice on BioSpace
November 12, 2020
BioSpace
Noxopharm Announces Pilot Study With Bristol Myers Squibb's Product - read this article along with other careers information, tips and advice on BioSpace
November 9, 2020
BioSpace
Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis - read this article along with other careers information, tips and advice on BioSpace
November 6, 2020
BioSpace
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer - read this article along with other careers information, tips and advice on BioSpace
June 3, 2020
BioSpace
New Data Reinforce Improved and Durable Clinical Responses of Orencia in Moderate-to-Severe Early Rheumatoid Arthritis Patients with Autoantibodies Linked to More Severe Disease - read this article along with other careers information, tips and advice on BioSpace
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.